Immature myeloid cells as targets for therapeutics to bacterial infection
Immature myeloid cells as targets for therapeutics to bacterial infection
批准号:
8415924
负责人:
Adrianus Wilhelmus Maria van der Velden
金额:
$19.42万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-02-15 至 2014-01-31
关键词:
Adoptive TransferAttentionBacterial InfectionsBiological MarkersBlood CirculationBone MarrowBromodeoxyuridineCD14 geneCardiovascular systemCell physiologyCellsCellular biologyCommunicable DiseasesDataDendritic CellsDevelopmentDiseaseDrug resistanceEffector CellEmigrationsEquilibriumGene DeletionHeterogeneityHumanITGAM geneImmuneImmune responseImmunityImmunosuppressionImmunosuppressive AgentsInfectionInfiltrationInflammatoryKnowledgeLabelLeadMalignant NeoplasmsMicrobial Drug ResistanceMononuclearMusMyelogenousMyeloid CellsNatural ImmunityNatureNitric OxideOutcomePathogenesisPeroxonitritePhasePhenotypePopulationPopulation HeterogeneityProductionProtein IsoformsReactive Oxygen SpeciesResearchRoleSalmonella entericaSalmonella typhimuriumSiteSuppressor-Effector T-LymphocytesSurfaceT cell responseT-LymphocyteTestingTherapeuticTissue HarvestingTissuesadaptive immunityantimicrobialarginasecell mediated immune responsechemokine receptorgranulocytehuman NOS2A proteinhuman diseasein vivoinhibitor/antagonistinnovationinsightmacrophagemicrobialmicrobicidemonocytemouse modelneutrophilnew therapeutic targetnovelnovel therapeutic interventionnovel therapeuticspathogenprotective effectresponsetherapeutic targettrafficking
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This proposal will determine the potential for myeloid-derived suppressor cells (MDSC) as novel therapeutic targets against infection. MDSC have received a significant amount of recent attention for their well-defined immunosuppressive role in cancer. The response of MDSC in infection is not as well characterized as in cancer, but studies do show a consistent immunosuppressive phenotype associated with MDSC infiltration at sites of infection. In some infections, MDSC may have an early protective role. MDSC have the plasticity necessary to differentiate into inflammatory monocytes, macrophages, myeloid dendritic cells and neutrophils. Thus, the dual nature of the MDSC response (immunosuppressive or protective) may be due to the morphologic and biomarker heterogeneity of these cells, such that the balance of MDSC phenotypes and functions at any point during infection may determine the outcome. We have obtained preliminary data demonstrating a large response of MDSC in mice infected with the bacterial pathogen Salmonella enterica serovar Typhimurium (S. Typhimurium). In addition, we have obtained preliminary evidence to suggest that while these cells may have an initial protective effect consistent with a role in innate immunity, they also have a potent inhibitory effect on T cells consistent with a role in suppression of adaptive immunity, which is a hallmark of S. Typhimurium infection. This application is built on the premise that MDSC can be targeted during infection in a temporal manner to capitalize on their protective role during the innate phase of the immune response and decrease their suppressive activity during the adaptive phase of the immune response. In Specific Aim 1, we will characterize the response and role of MDSC in mice infected with S. Typhimurium. This will involve documenting whether S. Typhimurium-induced MDSC suppress T cell function through production of nitric oxide or arginase-1. In Specific Aim 2, we will use a mouse model of infection with S. Typhimurium to determine if chemokine receptor CCR2 is required for emigration of MDSC out of bone marrow, and if MDSC can expand and mature in the periphery of mice infected with S. Typhimurium. In Specific Aim 3, we will specifically target MDSC expansion, activation and suppressive activity at the transition from innate to adaptive immune response as a novel therapeutic approach to infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of inflammatory monocytes in immunity and host defense against Salmonella
-
批准号:10463695
-
项目类别:
-
资助金额:$55.58万
-
财政年份:2020
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Role of inflammatory monocytes in immunity and host defense against Salmonella
-
批准号:10689679
-
项目类别:
-
资助金额:$55.58万
-
财政年份:2020
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Role of inflammatory monocytes in immunity and host defense against Salmonella
-
批准号:10252899
-
项目类别:
-
资助金额:$55.58万
-
财政年份:2020
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Role of inflammatory monocytes in Salmonella-induced colitis
-
批准号:10214501
-
项目类别:
-
资助金额:$19.6万
-
财政年份:2020
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Role of inflammatory monocytes in immunity and host defense against Salmonella
-
批准号:10028677
-
项目类别:
-
资助金额:$55.58万
-
财政年份:2020
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Role of inflammatory monocytes in Salmonella-induced colitis
-
批准号:10039094
-
项目类别:
-
资助金额:$23.59万
-
财政年份:2020
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Inhibition of T cells by Salmonella
-
批准号:9053439
-
项目类别:
-
资助金额:$39.01万
-
财政年份:2013
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Inhibition of T cells by Salmonella
-
批准号:8581524
-
项目类别:
-
资助金额:$36.54万
-
财政年份:2013
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Inhibition of T cells by Salmonella
-
批准号:8831585
-
项目类别:
-
资助金额:$39.01万
-
财政年份:2013
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Inhibition of T cells by Salmonella
-
批准号:8662188
-
项目类别:
-
资助金额:$38.99万
-
财政年份:2013
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Inhibition of T cells by Salmonella
-
批准号:9261461
-
项目类别:
-
资助金额:$39.01万
-
财政年份:2013
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
Immature myeloid cells as targets for therapeutics to bacterial infection
-
批准号:8243340
-
项目类别:
-
资助金额:$23.31万
-
财政年份:2012
-
负责人:Adrianus Wilhelmus Maria van der Velden
-
依托单位:
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈立达
-
依托单位: